Advertisement

Topics

Tercica Company Profile

03:36 EST 18th November 2017 | BioPortfolio

Tercica, Inc., based in Brisbane, Calif., is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the scientific and medical community to develop and commercialize therapeutics for growth and other endocrine disorders. In January 2006, less than four years after Tercica was founded, we commercially launched Increlex™ (mecasermin [rDNA origin] injection), or recombinant human Insulin-like Growth Factor-1 (rhIGF-1), in the United States. Increlex has received orphan drug exclusivity for its approved indication of the long-term treatment of growth failure in children with severe primary IGF-1 deficiency (Primary IGFD) or with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone. In December 2005, we submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMEA) for approval to market Increlex in the European Union (EU) where the product has also been granted "orphan product" designation. We are currently conducting broad-scale Phase III clinical studies to evaluate the safety and efficacy of Increlex in children with Primary IGFD, which is a less extreme form of the product's approved severe Primary IGFD indication. Tercica licensed rights to develop, manufacture and commercialize Increlex from Genentech, Inc. Beyond Increlex, we are building a franchise of endocrinology products. In October 2006, we entered into a worldwide strategic collaboration agreement in endocrinology with Ipsen S.A. Under terms of the agreement, Ipsen granted Tercica exclusive rights to sell Somatuline® Autogel® (lanreotide) in the United States, subject to approval by the US Food and Drug Administration (FDA), and in Canada. Tercica granted Ipsen exclusive rights to sell Increlex in all regions of the world except the United States, Japan, Canada, Taiwan and certain countries of the Middle East and North Africa, subject to approval by relevant regulatory authorities. Also through this collaboration agreement, the companies granted each other certain rights to their respective endocrinology pipelines. Somatuline® Autogel® is an injectable sustained-release formulation containing lanreotide, a somatostatin analogue which inhibits the excess secretion of growth hormone and IGF-1. It is approved for the treatment of acromegaly and neuroendocrine tumors in over 50 countries worldwide. In July 2006, Health Canada approved Somatuline® Autogel® for the long-term treatment of patients with acromegaly due to pituitary tumors who have had inadequate response to or cannot be treated with surgery and/or radiotherapy and for the relief of symptoms associated with acromegaly. A New Drug Application was submitted to the FDA for the same indication on October 30, 2006.

Location

2000 Sierra Point Parkway, Suite 400
Brisbane
CA
94005
United States of America

Contact

Phone: (650) 624-4900
Fax: (650) 624-4940
Email: hr@tercica.com


News Articles [0 Results]

None

Drugs and Medications [2 Associated Drugs and Medications listed on BioPortfolio]

Dysport [Tercica, Inc.]

These highlights do not include all the information needed to use DYSPORT™ for Injection safely and effectively. See full prescribing information for DYSPORT™ for Injection. DYSPORT™ for Inject...

Somatuline depot [Tercica, Inc.]

These highlights do not include all the information needed to use Somatuline Depot safely and effectively. See full prescribing information for Somatuline Depot. SOMATULINE® DEPOT (lanreotide) INJECT...

PubMed Articles [0 Results]

None

Clinical Trials [3 Associated Clinical Trials listed on BioPortfolio]

Prepubertal Children With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

This study is intended to determine whether twice daily weight based dosing with recombinant human insulin-like growth factor (rhIGF-1) will safely and effectively increase the growth of p...

Treatment of Children and Adolescents With Growth Failure Associated With Primary Insulin-Like Growth Factor-1 (IGF-1) Deficiency

This is an extension study to Tercica study MS301 and is intended to collect long term safety and efficacy data on the continued use of recombinant human insulin-like growth factor-1 (rh I...

IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex

This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Tercica, Inc. In collaboration with participating health care practitioners, ...

Companies [1 Associated Companies listed on BioPortfolio]

Tercica

Tercica, Inc., based in Brisbane, Calif., is a biopharmaceutical company committed to improving endocrine health. We are helping patients by partnering with the scientific and medical community to dev...

More Information about "Tercica" on BioPortfolio

We have published hundreds of Tercica news stories on BioPortfolio along with dozens of Tercica Clinical Trials and PubMed Articles about Tercica for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tercica Companies in our database. You can also find out about relevant Tercica Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Pancreatitis
Pancreatitis Acute pancreatitis is inflammation of the pancreas caused by the release of activated pancreatic enzymes. Common triggers are biliary tract disease and chronic heavy alcohol intake.  Diagnosis is based on clinical presentation...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...


Corporate Database Quicklinks



Searches Linking to this Company Record